Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Head & Neck 2

Conditions

Neoplasms 19Breast Neoplasms 15Prostatic Neoplasms 14Colorectal Neoplasms 14Hematopoietic and Lymphatic System Neoplasm 12Lung Neoplasms 10Ovarian Neoplasms 5Multiple Myeloma 5Hematologic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Malignant Solid Neoplasm 4Hematopoietic and Lymphoid System Neoplasm 4Depression 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Laryngeal Neoplasms 3Head and Neck Neoplasms 3Anxiety Disorders 3Anatomic Stage I Breast Cancer AJCC v8 3Advanced Malignant Solid Neoplasm 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Motor Activity 2Melanoma 2Malignant Female Reproductive System Neoplasm 2Leukemia 2

Interventions

Cisplatin 55Carboplatin 49pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Docetaxel 17Cetuximab 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 12Radiation 11Sorafenib 10Platinum 10130-nm albumin-bound paclitaxel 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Sunitinib 8Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma × Interviews as Topic × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06662058 2026-04-23

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Emory University

Phase NA Recruiting
118 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡